

PATENT  
PC25214A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 3rd day of February, 2003.

By

*Deanna L. Shields*  
(Signature of person mailing)

*Deanna L. Shields*  
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----  
IN RE APPLICATION OF:

Nicholas Pullen, et al.

Examiner: To Be Assigned

SERIAL NO.: 10/663,082

Art Unit: To Be Assigned

FILED: September 16, 2003

FOR: COMBINATIONS OF ATORVASTATIN  
AND  $\alpha 1$  ADRENERGIC RECEPTOR  
ANTAGONISTS

-----  
Commissioner For Patents

P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.97(b)(3)

Sir:

Pursuant to the provisions of 37 C.F.R. §1.97(b)(3), Applicant petitions for the entry and consideration of the supplemental Information Disclosure Statement transmitted herewith in the above-identified case.

WO 99/11260 discloses combinations of atorvastatin and antihypertensive agents.

WO 98/30560 discloses quinoline and quinazoline compounds useful in treating benign prostatic hyperplasia.

WO 03/76427 discloses quinazoline compounds useful in treating benign prostatic hyperplasia.

US 2002/004521 discloses the use of HMG-CoA reductase inhibitors in the treatment of benign prostatic hyperlasia.

IT 1,238,011 B1 discloses compositions comprising HMG-CoA reductase inhibitors for treating benign prostatic hyperlasia.


Pursuant to the provisions of M.P.E.P. 1302.12, it is requested that the references listed on the attached form, which complies with PTO-FB-A820, be included in the "References Cited" portion of any patent issuing from this application.

Pursuant to the provisions of 37 C.F.R. §1.97(e)(1), Applicant's undersigned representative certifies that each item of information contained in the supplemental Information Disclosure Statement was first cited in a counterpart foreign application not more than three (3) months prior to the date of the filing of this supplemental Information Disclosure Statement.


Pursuant to the provisions of 37 C.F.R. §1.97(c), no fee for the filing of this supplemental Information Disclosure Statement is due.

Respectfully submitted,

Date: February 3, 2004

  
Carl J. Goddard  
Attorney for Applicant  
Reg. No. 39,203  
Tel.: (860) 441-4902

PFIZER INC  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, CT 06340  
(860) 441-4902



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									ATTY. DOCKET NO. PC25214A			SERIAL NO. 10/663,082					
									APPLICANT Nicholas Pullen, et al.								
									FILING DATE September 16, 2003			GROUP To be assigned					
U.S. PATENT DOCUMENTS																	
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
	US	0	0	0	4	5	2	1	01/10/02	Weisman et al.	514	423					
FOREIGN PATENT DOCUMENTS																	
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
													YES	NO			
	IT	1	2	3	8	0	1	1	21.06.93	Italy	A-61K						
	WO	9	9	1	1	2	6	0	11.03.99	International	A61K	31/40					
	WO	9	8	3	0	5	6	0	16.07.98	International	C07D	409/04					
	WO	03	0	7	6	4	2	7	18.09.03	International	C07D	401/04					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																	
EXAMINER																	
DATE CONSIDERED																	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																	